# A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

> **NCT05252520** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-77474462

## Key facts

- **NCT ID:** NCT05252520
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-01
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The development of bermekimab in Immunology is stopped
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252520, "A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05252520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*